Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-CD19 CAR-NK cells QN-019a

A preparation of allogeneic natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with potential immunomodulating and antineoplastic activities. Upon administration, the allogeneic anti-CD19 CAR-NK cells QN-019a recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	allogeneic CD19-targeting CAR-NK cells QN-019a
Code name:	QN 019a QN-019a QN019a

allogeneic anti-CD19 CAR-NK cells QN-019a

Search NCI's Drug Dictionary